论文部分内容阅读
生物技术和生物制药已经极大地改变了制药工业的格局。由于生物技术和生物制药在促进经济增长和产生社会效益方面存在的巨大潜力,使得生物经济的发展已成为美国政府优先考虑的民生问题。目前,美国制药和生物制药公司正在研发900多种生物制剂和疫苗,适用范围包括抗肿瘤、自身免疫性疾病,心血管疾病和感染性疾病等100多种疾病。本文综述当前美国生物制药领域的进展,并对美国政府的《国家生物经济蓝图》进行探讨。
Biotechnology and biopharmaceuticals have dramatically changed the landscape of the pharmaceutical industry. Due to the tremendous potential of biotechnology and biopharmaceuticals in promoting economic growth and social benefits, the development of bioeconomy has become a priority livelihood issue for the U.S. government. At present, U.S. pharmaceutical and biopharmaceutical companies are developing more than 900 biological agents and vaccines, covering more than 100 diseases including anti-tumor, autoimmune diseases, cardiovascular diseases and infectious diseases. This article reviews current developments in the biopharmaceutical industry in the United States and explores the “blueprint for national bioeconomy” of the U.S. government.